| Psoriasis vulgaris
Hadlima vs Ilumya
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Hadlima vs Ilumya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIlumya has a higher rate of injection site reactions vs Hadlima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ilumya but not Hadlima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hadlima
Ilumya
At A Glance
SC injection
Every other week
TNF-alpha blocker
SC injection
Every 12 weeks
IL-23 antagonist
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Psoriasis vulgaris 100 mg SC at Weeks 0, 4, and every 12 weeks thereafter.
Contraindications
—
- Previous serious hypersensitivity reaction to tildrakizumab-asmn or any excipient
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Most common (>=1%) Upper respiratory infections, injection site reactions, diarrhea
Serious Hypersensitivity reactions, infections
Pharmacology
TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, thereby suppressing the release of proinflammatory cytokines and chemokines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hadlima
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ilumya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Hadlima
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Ilumya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hadlima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ilumya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hadlima.
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HadlimaView full Hadlima profile
IlumyaView full Ilumya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.